WAVE Life Sciences Ltd.
WVE
$5.73
-$0.34-5.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -94.06% | 121.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -94.06% | 121.78% | |||
| Cost of Revenue | 8.12% | -10.18% | |||
| Gross Profit | -433.18% | 74.15% | |||
| SG&A Expenses | 12.11% | 5.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.39% | -5.65% | |||
| Operating Income | -135.80% | 44.57% | |||
| Income Before Tax | -165.86% | 50.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -165.86% | 50.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -165.86% | 50.94% | |||
| EBIT | -135.80% | 44.57% | |||
| EBITDA | -139.50% | 45.24% | |||
| EPS Basic | -160.94% | 55.86% | |||
| Normalized Basic EPS | -160.74% | 55.83% | |||
| EPS Diluted | -160.94% | 55.86% | |||
| Normalized Diluted EPS | -160.74% | 55.83% | |||
| Average Basic Shares Outstanding | 1.92% | 11.11% | |||
| Average Diluted Shares Outstanding | 1.92% | 11.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||